IDA blend vs Netherlands: Access to anti-retroviral drugs, male
IDA blend
74.0%
in 2024
Netherlands
89.0%
in 2023
IDA blend rank
14th
Netherlands rank
17th
Access to anti-retroviral drugs, male over time
- IDA blend
- Netherlands
How they compare
Netherlands currently reports 89.0% against 74.0% in IDA blend, a difference of 15.0%.
That makes Netherlands's figure about 1.2 times IDA blend's.
Across all 24 years both countries report, Netherlands has been ahead every year.
IDA blend ranks 14th and Netherlands ranks 17th of 19 groups.
Netherlands has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | IDA blend | Netherlands | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 5.5% | 50.8% | 45.3% | Netherlands |
| 2010s | 38.5% | 76.8% | 38.3% | Netherlands |
| 2020s | 66.1% | 88.2% | 22.1% | Netherlands |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher access to anti-retroviral drugs, male, IDA blend or Netherlands?
- Netherlands, at 89.0% against 74.0% in IDA blend as of 2023.
- What is the difference in access to anti-retroviral drugs, male between IDA blend and Netherlands?
- 15.0%, with Netherlands ahead.
- How many years of comparable data are there for IDA blend and Netherlands?
- 24 years are reported by both, from 2000 to 2023.
- How do IDA blend and Netherlands rank globally for access to anti-retroviral drugs, male?
- IDA blend ranks 14th and Netherlands ranks 17th of 19 groups.
- Where does this data come from?
- UNAIDS estimates, published as Access to anti-retroviral drugs, male (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The percentage of adult males living with HIV who are receiving antiretroviral therapy.